Djamel Bensmail

Prof. Dr. Djamel Bensmail


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Annals of Physical and Rehabilitation Medicine
Verified
Journal Article
Closed access
JLJonathan Levy
Jonathan Levy
HPH. Prigent
H. Prigent
DBDjamel Bensmail
Djamel Bensmail

1 July 2019 in Annals of Physical and Rehabilitation Medicine
Verified
Journal Article
Closed access
JLJonathan Levy
Jonathan Levy
FMFranco Molteni
Franco Molteni
GCGiovanni Cannaviello
Giovanni Cannaviello
TLThibaud Lansaman
Thibaud Lansaman
NRNicolas Roche
Nicolas Roche
DBDjamel Bensmail
Djamel Bensmail

12 April 2023 in Toxins
Verified
Journal Article
Open access
PDF file
DBDjamel Bensmail
Djamel Bensmail
PKPierre Karam
Pierre Karam
AFAnne Forestier
Anne Forestier
JLJean-Yves Loze
Jean-Yves Loze
JLJonathan Levy
Jonathan Levy
There are limited real-world data on the use of botulinum toxin type A (BoNT-A) in patients with multiple sclerosis (MS). Accordingly, this nationwide, population-based, retrospective cohort study aimed to describe BoNT-A treatment trends in patients with MS between 2014 and 2020 in France. This study extracted data from the French National Hospital Discharge Database (Programme de Médicalisation des Systèmes d’Information, PMSI) covering the entire French population. Among 105,206 patients coded with MS, we identified those who received ≥1 BoNT-A injection, administered within striated muscle for MS-related spasticity and/or within the detrusor smooth muscle for neurogenic detrusor overactivity (NDO). A total of 8427 patients (8.0%) received BoNT-A injections for spasticity, 52.9% of whom received ≥3 BoNT-A injections with 61.9% of the repeated injections administered every 3 to 6 months. A total of 2912 patients (2.8%) received BoNT-A injections for NDO, with a mean of 4.7 injections per patient. Most repeated BoNT-A injections within the detrusor smooth muscle (60.0%) were administered every 5 to 8 months. There were 585 patients (0.6%) who received both BoNT-A injections within striated muscle and the detrusor smooth muscle. Overall, our study highlights a broad range of BoNT-A treatment practices between 2014 and 2020 in patients with MS.

29 November 2023 in Toxins
Verified
Journal Article
Open access
PDF file
LJLuis Jorge Jacinto
Luis Jorge Jacinto
ABAlexander Balbert
Alexander Balbert
DBDjamel Bensmail
Djamel Bensmail
Stefano CardaStefano Carda
Stefano Carda
NDNathalie Draulans
Nathalie Draulans
RRRajiv Reebye
Rajiv Reebye
The objective of this article is to introduce the GO-FAST Tool (developed by the Toxnet group) to clinicians working in the field of neurological rehabilitation, specifically post-stroke spasticity management. The concepts utilized in the Tool and described in this article can be broadly grouped into five topics: the principles of patient-centred goal-setting; an algorithm for setting SMART (specific, measurable, attainable, realistic, and timed) treatment goals; goal-related target muscles and botulinum toxin type A dose determinants; goal attainment follow-up, scoring, and interpretation; and the multimodal approach to spasticity management. The Tool can enhance clinical practice by providing guided assistance with goal-setting and target muscle selection for botulinum toxin type A treatment. It also provides support with the follow-up evaluation of goal attainment and calculation of treatment success. The Tool is designed to be used by clinicians with varying levels of expertise in the field of neurological rehabilitation and post-stroke spasticity management, from those who are new to the field to those with many years of experience. A case study is presented in the Results Section of the article to illustrate the utility of the Tool in setting SMART treatment goals in the management of patients with post-stroke spasticity.

24 August 2022 in Toxins
Verified
Journal Article
Open access
PDF file
IBInes Baccouche
Ines Baccouche
DBDjamel Bensmail
Djamel Bensmail
ELEmilie Leblong
Emilie Leblong
BFBastien Fraudet
Bastien Fraudet
CAClaire Aymard
Claire Aymard
JLJonathan Levy
Jonathan Levy
Spasticity is one of the most disabling symptoms in multiple sclerosis (MS). Botulinum toxin injection (BTI) is a first-line treatment for focal spasticity. There is a lack of evidence of a functional improvement following BTI in MS-related spasticity. To describe goal-setting for BTI in MS, and evaluate the degree of attainment, using goal attainment scaling (GAS) 4-to-6 weeks after injection session, a one-year multi-center retrospective observational study assessing goal-setting and achievement during BTI session in spastic patients with MS was set up. Following the GAS method, patients and their physicians set up to three goals and scored their achievement 4 to 6 weeks thereafter. Commonly used goals from three centers were combined into a standardized list and 125 single BTI sessions were analyzed. The most frequent goals regarded lower limb (LL) impairments (equinovarus foot, toe claw) or locomotion (stability, walking distance, clinging) and accounted for 89.1%, versus 10.9% for upper limb (UL), mostly for mild-to-moderate MS. Overall, goals were frequently achieved (85.77%) mainly when related to gait and mobility rather than hygiene and ease of care. This study gives an overview on the most frequent, relevant, and achievable goals to be set in real-life practice of BTI for spasticity management in MS.

1 December 2016 in Annals of Physical and Rehabilitation Medicine
Verified
Journal Article
Closed access
JLJonathan Levy
Jonathan Levy
GBGratiane De Brier
Gratiane De Brier
CHCaroline Hugeron
Caroline Hugeron
TLThibaud Lansaman
Thibaud Lansaman
DBDjamel Bensmail
Djamel Bensmail